Skip to main content

Britain's navy in the event of a no-deal Brexit to defend fishing waters

LONDON (Reuters) - In the event that the Brexit transition phase ends on Dec. 31 without an agreement on future relations with the European Union, four Royal Navy patrol ships are on standby to defend Britain's fishing waters, the Ministry of Defence (MOD) said.

The step attracted criticism from lawmakers within the Conservative Party of British Prime Minister Boris Johnson, but was brushed off by the French government.

"Keep calm and carry on," said an Elysée official, using a British wartime slogan.

Where no trade agreement is reached, questions are raised about potential skirmishes between British and international fishing vessels, with current transitional rules allowing EU boats access to British waters set to expire by the end of the year.

"An MOD spokesman said The MOD has carried out comprehensive training and preparation to ensure that Defence is ready at the end of the Transition Phase for a variety of scenarios.

The 80-meter-long navy vessels would have the authority to detain and inspect EU fishing vessels operating within the Exclusive Economic Zone (EEZ) of Britain, which is capable of extending 200 miles (320 km from shore.

The Guardian newspaper announced earlier that in the event of EU fishing boats joining the EEZ, two vessels will be deployed at sea with another two on standby.

The step was dubbed 'irresponsible' by Tobias Ellwood, a Conservative Party lawmaker who chairs the defence select committee of the British parliament.

"We are only faced with the possibility of... Our overstretched Royal Navy is squaring over fishing vessel rights to a close NATO ally,' he told BBC radio. "Our opponents must have really enjoyed this."

On Thursday, a French minister said that France will reward its fishermen and take other steps to assist them in the event of a breakdown of the trade agreement negotiations, in an attempt to prevent conflicts at sea.

Britain left the EU in January, but remains a member of the bloc's single market and customs union under the terms of its withdrawal agreement until the transition period ends on Dec. 31.

Johnson and Ursula von der Leyen, the president of the European Commission, said on Friday that it was now doubtful that a trade agreement would be negotiated.

Comments

New comments are not allowed.

Popular posts from this blog

The CEO of AstraZeneca plans to conduct the latest global COVID-19 vaccine trial: Bloomberg

(Reuters) - An additional global trial to test the effectiveness of its COVID-19 vaccine using a lower dose is likely to be conducted by AstraZeneca, its chief executive was quoted as saying on Thursday amid concerns about the outcome of its late-stage review. AstraZeneca could start a new study to test a lower dose of its vaccine that worked better than a full dosage, Pascal Soriot told Bloomberg News, instead of adding the trial to an existing U.S. phase. "We have to validate this now that we have discovered what looks like a better efficacy, so we need to do an additional study," he said, adding that the latest, likely global, study could be quicker because it would require less subjects as the effectiveness was already established to be high. The news comes as AstraZeneca faces concerns about its success rate that some analysts claim could impede its chances of securing rapid regulatory approval from the U.S. and EU. Several scientists have raised concerns about the r
Post a Comment
Read more

In 'challenging point' Brexit trade negotiations, British minister says

LONDON (Reuters) - Brexit trade negotiations are in a difficult process, and only if the European Union understands that Britain is a sovereign nation will an agreement be reached, said Business Secretary Alok Sharma. "We're at a critical stage," Sky TV told Sharma. "It is fair to say that we are in a difficult phase, that there are still some difficult problems to solve." "We have always said right from the beginning of this process that only if the EU recognizes that the UK is a sovereign independent nation can an agreement be reached," Sharma said. "It is on the basis of that a deal will be done."
Post a Comment
Read more

AstraZeneca to purchase Alexion to grow in immunology for $39 billion

FRANKFURT (Reuters) -Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals in the biggest transaction ever for $39 billion, diversifying its fast-growing cancer sector in a gamble on medicines for rare diseases and immunology. The deal comes a week after AstraZeneca said it was undertaking more testing to confirm whether its COVID-19 vaccine could be 90% successful, potentially delaying its introduction, and was introduced in Britain as a competing shot from Pfizer and approved for use in the United States . On Saturday, the British company said Alexion shareholders will receive $60 in cash and around $115 worth of equity per share - either in ordinary shares exchanged in the UK by AstraZeneca or in American Depositary Shares denominated in dollars. That implies a total price of $175 per share based on a reference average ADR price of $54.14. Alexion shares closed on Friday at about $121 apiece. "It's a tremendous opportunity for us to accelera
Post a Comment
Read more